0001209191-23-028813.txt : 20230511 0001209191-23-028813.hdr.sgml : 20230511 20230511170444 ACCESSION NUMBER: 0001209191-23-028813 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230428 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 23912079 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-28 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO STREET SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer 1 Common Stock 2023-04-28 5 A 0 E 317 66.88 A 426213 D Common Stock 2023-05-09 4 M 0 30000 67.81 A 456213 D Common Stock 2023-05-09 4 S 0 13626 94.22 D 442587 D Common Stock 2023-05-09 4 S 0 14964 95.49 D 427623 D Common Stock 2023-05-09 4 S 0 1410 95.90 D 426213 D Common Stock 2023-05-10 4 M 0 30000 67.81 A 456213 D Common Stock 2023-05-10 4 S 0 21453 94.65 D 434760 D Common Stock 2023-05-10 4 S 0 8547 95.34 D 426213 D Common Stock 247333 I Shares held by Jean-Jacques Bienaime Family Trust Common Stock 100 I Shares held as UTMA custodian for child Common Stock 100 I Shares held as UTMA custodian for child Stock Option (Right to Buy Common Stock) 67.81 2023-05-09 4 M 0 30000 0.00 D 2013-11-15 2023-05-14 Common Stock 30000 99130 D Stock Option (Right to Buy Common Stock) 67.81 2023-05-09 4 M 0 30000 0.00 D 2013-11-15 2023-05-14 Common Stock 30000 69130 D Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. The price in column 4 is the weighted average price. The price actually received ranged from $93.85 to $94.83. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $94.86 to $95.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $95.86 to $95.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $94.12 to $95.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $95.115 to $95.81. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2023-05-11